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Abstract 
OBJECTIVE We aimed to develop an automatic image interpretation system based on a 
deep convolutional neural network (CNN) which can accurately predict future cognitive 
decline in mild cognitive impairment (MCI) patients using flurodeoxyglucose and florbetapir 
positron emission tomography (PET).  
METHODS PET images of 139 patients with AD, 171 patients with MCI and 182 
normal subjects obtained from Alzheimer’s Disease Neuroimaging Initiative database were 
used. Deep CNN was trained using PET images of AD and normal controls. Feature 
extraction and spatial normalization which have been routinely used in conventional 
quantitative analyses were unnecessary for our approach. Cognitive outcome of MCI subjects 
was predicted using this network. The prediction accuracy of the conversion of mild 
cognitive impairment to AD was compared with conventional feature-based quantification 
approach. Output variables of the network were correlated with the longitudinal change of 
cognitive measurements.  
RESULTS Accuracy of prediction (84.2%) for conversion to AD in MCI patients 
outperformed conventional feature-based quantification approaches. ROC analyses revealed 
that performance of CNN-based approach was significantly higher than that of the 
conventional quantification methods (p < 0.05). Output scores of the network were strongly 
correlated with the longitudinal change in cognitive measurements (p < 0.05).  
CONCLUSIONS Deep CNN could accurately predict future cognitive declines in MCI 
patients by automatically interpreting PET images. These results show the feasibility of deep 
learning as a practical tool for developing predictive imaging biomarker.  
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Abbreviations 
AD Alzheimer’s disease 
MCI Mild cognitive impairment 
FDG   18F-fluorodeoxyglucose 
AV-45 18F-florbetapir 
CNN Convolutional neural network  
ADNI  Alzheimer’s Disease Neuroimaging Initiative 
NC Normal control 
CDR-SB Clinical Dementia Rating Sum of Boxes  
ADAS-Cog Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13-item  
FAQ Functional Activities Questionnaire  
MMSE Mini-Metal Status Examination  
ROC  Receiver operating characteristic  
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Introduction 
Recent treatment strategies for Alzheimer’s disease (AD) are aimed at slowing cognitive 
decline and are focused on the pre-dementia stage which includes mild cognitive impairment 
(MCI) 1. However, as the etiology of MCI is heterogeneous, MCI patients show different 
rates of cognitive decline, and even some never convert to AD 2. Thus, it is a matter of utmost 
importance to identify the patients with MCI who would benefit from treatment. So far, 
several studies have investigated a number of imaging biomarkers that can predict whether a 
patient with MCI will convert to AD. They include brain metabolism and amyloid load 
measured by 18F-fluorodeoxyglucose (FDG) and 18F-florbetapir (AV-45) positron emission 
tomography (PET), respectively 3-6. Previous studies have used quantitative parameters or 
visual assessment of the brain images for predicting MCI patients who would covert to AD. 
However, visual analysis cannot provide quantitative and objective data and quantitative 
analyses commonly require complicated processing 7-10.  
In this study, we developed a deep convolutional neural network (CNN) based method, a 
type of deep learning, for the prediction of cognitive decline. Recent advances in CNN have 
dramatically improved image recognition field 11. We applied CNN to FDG and AV-45 PET 
images to predict cognitive decline in MCI patients. Our automated method was designed to 
discriminate patients groups classified according to the cognitive outcome with minimized 
image processing. In addition, it could provide a quantitative biomarker combining both the 
FDG and AV-45 PET information. We showed that the CNN-based biomarker strongly 
correlated with future cognitive decline.  
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Methods 
Subjects 
The data used in this study included subjects recruited in Alzheimer’s Disease 
Neuroimaging Initiative-II (ADNI-2) with available baseline data on FDG and AV-45 PET 
(http://adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, 
led by Principal Investigator Michael W. Weiner, MD, VA Medical Center and University of 
California San Francisco. Subjects have been recruited from over 50 sites across the US and 
Canada. The primary purpose of ADNI has been to test whether serial MRI, PET, other 
biological markers, and clinical and neuropsychological assessment can be combined to 
measure the progression of MCI and early AD. For up-to-date information, see 
http://www.adni-info.org. Written informed consent to cognitive testing and neuroimaging 
prior to participation was obtained, approved by the institutional review boards of all 
participating institutions.   
For diagnostic classification and learning the CNN, we firstly selected patients with AD 
and healthy subjects who had baseline FDG and AV-45 PET scans. We also selected MCI 
patients who had baseline FDG and AV-45 PET scans and 3-year follow-up clinical 
evaluation. This resulted in 182 normal controls (NCs), 139 AD patients and 171 MCI 
subjects. Based on whether the MCI patients would convert to AD within 3 years, MCI 
patients were grouped as MCI converters and nonconverters.  
 Cognitive function of the subjects was evaluated using Clinical Dementia Rating Sum of 
Boxes (CDR-SB), Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13-item 
(ADAS-Cog), Functional Activities Questionnaire (FAQ), and Mini-Metal Status 
Examination (MMSE). As we interested in whether CNN-based baseline PET biomarkers 
would be associated with longitudinal cognitive decline, longitudinal changes of cognitive 
measurements were also assessed at 1 year and 3 years after the baseline study.  
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FDG PET and AV-45 PET 
All the PET images were downloaded from ADNI database at the most advanced 
preprocessing stage. FDG PET images were acquired 30 to 60 min and AV-45 PET images 
were acquired 50 to 70 min after the injection. The FDG and AV-45 PET images were co-
registered to each other, averaged across the time frames, standardized to have same voxel 
size (1.5 x 1.5 x 1.5 mm). PET images were acquired in the 57 sites participating in ADNI, 
scanner-specific smoothing was additionally applied 12. As the processing did not include 
nonlinear spatial warping, size and shape of the brains were not changed after the 
preprocessing. These preprocessed images could be downloaded from ADNI database and we 
used them for deep CNN training and testing as they are.  
 
Study design 
The main purpose of this paper was to develop a deep CNN-based method for prediction 
of cognitive decline and selection of subjects who would eventually convert to AD. Before the 
testing of MCI conversion, the deep CNN was trained using PET images of AD and NC 
subjects. For discrimination between MCI converter and nonconverter, the pre-trained network 
trained by AD/NC data was directly used as the imaging features of MCI converter would be 
similar with those of AD. The nodes of the output layer were only reassigned to MCI converter 
and nonconverter. All the PET images of MCI subjects were tested whether they would convert 
to AD or not. Therefore, our deep CNN was a classifier independent from the training data to 
discriminate between MCI converter and nonconverter (figure 1). In addition, we also obtained 
a quantitative score for MCI converter. The quantitative value of the final output of the network 
was defined as ConvScore, a score that indicates how close inputted baseline images are to AD. 
The score can be expected to be utilized for a predictive biomarker.   
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Figure 1 Framework for predicting cognitive decline in mild cognitive impairment patients. (A) Deep 
convolutional neural network architecture is applied to the two PET images, FDG and florbetapir (AV-45). Each 
layer, features can be extracted by 3-dimensional convolution and activation (ReLU) function. Multilayer 
convolutions yield 1-dimensional output and the last layer have two nodes, which correspond to Alzheimer’s 
disease (AD) and normal control (NC). (B) Deep CNN was trained from PET data of AD and NC. 10-fold cross 
validation was used. After the training, the trained network was directly used for the classification between mild 
cognitive impairment (MCI) converter and nonconverter. Thus, the network was independent from the PET data 
of MCI patients. Prediction accuracy for MCI conversion was assessed. Receiver operating characteristic (ROC) 
analysis was also performed. 
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Preparation for 3-dimensional deep convolutional neural network  
Recently, classifications in image data using deep convolutional neural network (CNN) 
have demonstrated outstanding performances compared with previous machine learning 
approaches. The main reason for superior performance is originated from shift invariant 
property of CNN and multi-layered interpretation, which is closely related with actual human 
visual perception. In particular, the shift invariant property originated from the convolution 
operator can efficiently detect target objects distributed on overall spatial space. Deep CNN 
can be easily extended into 3 dimensional volume data when including natural image features 
such as video processing 11. In this paper, we aimed to classify PET brain dataset using 3D 
CNN model. Because 3D CNN has robust shift invariant property, the detection of specific 
features in the 3 dimensional spaces can be effectively performed. Furthermore, in our 3D 
CNN model, we used two different kinds of PET data as multi-channel data (2 channels) to 
exploit diverse features from FDG and AV-45.  
The one of the most important part of our approach is simplified pre-processing. After the 
aforementioned preprocessing including co-registeration of two modalities, voxel-size 
standardization and scanner-specific smoothing, we simply rescaled the image data. The 
rescaling included two procedures: (1) Each modality (FDG and AV-45) is rescaled by the 
range from 0 to 255, and then (2) mean scalar value from a group of each modality is 
subtracted from all subjects. After two-step pre-processing, 3D volume data from FDG and 
AV-45 ( 160 x 160 x 96 volume) are concatenated as a 4D volume (160 x 160 x 96 x 2) to be 
used for input argument of the network.  
 
 
Network architecture 
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The architecture of our network is as follows: we constructed three convolution layers 
followed by both maximum pooling and ReLU, and one fully connected layer. The sizes of 3-
D convolution filter are (first layer: 7 × 7 × 7, second layer: 7 × 7 × 7, third layer: 6 × 6 ×
6), respectively. The number of feature maps is increased as 2, 64, 128, and 512 proportional 
to the depth of layer.  
The relationship of 3-D convolution related with feature maps between input and output 
of CNN can be represented as 
𝑂[𝑥, 𝑦, 𝑧, 𝑓] = 𝐶𝑖(𝐼, 𝑠) = ∑ ∑ ∑ ∑ 𝐼[𝑥
′ − 𝑥, 𝑦′ − 𝑦, 𝑧′ − 𝑧, 𝑓′]𝑠[𝑥′, 𝑦′, 𝑧′, 𝑓′, 𝑓]
𝑁𝑓
𝑓′=1
𝑁𝑧
𝑧′=1
𝑁𝑦
𝑦′=1
𝑁𝑥
𝑥′=1
, 
where 𝑖 is the stride number which is sliding unit of convolution operation, 𝐼 ∈
𝑅𝑁𝑥×𝑁𝑦×𝑁𝑧×𝑁𝑓 is an input volume for the specific convolution layer, 𝑂 ∈
𝑅(𝑁𝑥−𝑊𝑥+1)×(𝑁𝑦−𝑊𝑦+1)×(𝑁𝑧−𝑊𝑧+1)×𝑁𝑓
′
 is an output volume from the specific convolution 
layer, 𝑠 ∈ 𝑅𝑊𝑥×𝑊𝑦×𝑊𝑧×𝑁𝑓×𝑁𝑓
′
 is a filter bank for 3D volume with multiple feature maps, 
(𝑊𝑥, 𝑊𝑦, 𝑊𝑧) are the spatial dimensions (𝑥, 𝑦, 𝑧) of filter bank, (𝑁𝑥, 𝑁𝑦, 𝑁𝑧) are the spatial 
dimensions of input volume, (𝑁𝑓 , 𝑁𝑓
′) are the number of feature maps before convolutional 
layer and after convolutional layer, respectively. For example, in the case of our first 
convolution layer, let we define 𝐼  from a subject has 𝐼 ∈ 𝑅160×160×160×2 (increased 
dimension along z-axis by zero-padding), and the output 𝑦 ∈ 𝑅39×39×39×64 from 
convolution layer (stride = 4) consisting of 𝑠 ∈ 𝑅7×7×7×2×64 filter (dimension of x-axis, 
dimension of y-axis, dimension of z-axis, # of feature maps in input, # of feature maps in 
output). After convolution operation, ReLU and max pooling operations will be performed on 
the output of convolution given as 
𝑂[𝑥, 𝑦, 𝑧, 𝑓] = 𝑅(𝐼) = max (0, 𝐼[𝑥, 𝑦, 𝑧, 𝑓]) 
𝑂[𝑥, 𝑦, 𝑧, 𝑓] = 𝑀𝑠(𝐼) = max
−⌊𝑠/2⌋≤𝑖≤−⌊𝑠/2⌋,−⌊𝑠/2⌋≤𝑗≤−⌊𝑠/2⌋,−⌊𝑠/2⌋≤𝑘≤−⌊𝑠/2⌋
𝐼[𝑥 + 𝑖, 𝑦 + 𝑗, 𝑧 + 𝑘, 𝑓]  
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where 𝑅 is ReLU operator, 𝑀𝑠 is max pooling operator. In case of max pooling operator, 
the stride operation (interleaved sliding of positions) could be accompanied for reduction of 
network size. In practical point of views, the ReLU keeps positive input values whereas 
negative input values are changed into 0s. The max pooling operation chooses the maximum 
value from pre-defined region of 3-D box, and puts this value into reduced sized feature map. 
Using aforementioned operations, we can construct efficient multi-layer CNN described 
as 
𝑂(𝐼; 𝒔) = 𝑪(𝐼; 𝒔) = 𝑆𝑜𝑓𝑡(𝐹𝐶(𝑅 ∘ 𝐶3(𝑀3 ∘ 𝑅 ∘ 𝐶2(𝑀3 ∘ 𝑅 ∘ 𝐶1(𝐼, 𝑠1), 𝑠2), 𝑠3), 𝑠4)) 
where ∘ is the sequential composition of operators, 𝐹𝐶 is a fully connected layer, 𝒔 is an 
augmented volume of each level’s filter bank (𝒔 = (𝑠1, 𝑠2, 𝑠3, 𝑠4)) , Soft is the softmax 
function. For the training phase, we choose supervised learning, so the functionals (𝑦(𝑥)) 
from the CNN are set to be one for AD and two for NC. The total loss function, 𝐿(𝒔), to be 
minimized is described as  
𝐿(𝒔) =
1
𝑁𝑠
∑ 𝑙(𝑂𝑖, 𝑪(𝐼𝑖; 𝒔)),
𝑁𝑠
𝑖=1
 
where 𝑙(𝑂𝑖, 𝒅𝒊) is a loss function between true label (𝑂𝑖) with respect to input (𝒅𝒊), and 𝑁𝑠 
is the total number of training data set. 
This supervised learning are conducted by stochastic gradient descent (SGD) algorithm 13, 
the source code of which is distributed by MatConvNet (Version 1.0-beta 16) 14. The detailed 
explanation about backpropagation and gradient descent can be referred by reference 14. 
Training of the network was performed by imaging data of AD and NC. We choose the 10 
fold cross-validation for supervised learning, thus, 10% of the dataset were used for the 
validation. The network was trained for 50 epochs. The momentum parameter for SGD was 
set to 0.9. The learning rate was initially 1x10-5 and logarithmically decreased to 1x10-7. 
Before passing through the last layer, softmax function, values of two nodes indicate scores 
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for AD and NC (or MCI converter and nonconverter), respectively. The quantitative value of 
‘AD node’ was defined as ConvScore, a score that indicates how input PET data are close to 
AD or MCI converter.  
 
Training and validation of classification between AD and NC  
Our proposed network was learned from the image data of AD and NC. Ten-fold cross-
validation was implemented to evaluate the performance and optimize the network 
parameters. Subjects were randomly divided into 10 subsets including a subset for testing and 
remaining nine subsets for training. Training and evaluating process were repeated and 
classification performance was evaluated using results of testing subsets. For training, 
convolutional layers and fully-connected layers were initialized with random weights. To 
increase the performance for test sets, training data were augmented as deep CNN-based 2-
dimensional image recognition tasks 15. Considering anatomical symmetry of the brain, the 
images were left-right flipped to augment the training set. As 90% of AD/NC PET image data 
were included in the training set for each fold, 289 x 2 (or 288 x 2) image pairs were used for 
the training. The remained 32 (or 31) image pairs were included in the validation set.  
Sensitivity, specificity and accuracy of the classification were calculated by results from 
all validation subsets. After the softmax function, if the probability score of AD was higher 
than 0.5, predictive diagnosis was ‘AD’. In addition, receiver operating characteristic (ROC) 
analysis was performed using ConvScore, output variables of ‘AD node’.  
 
Prediction of cognitive decline in MCI subjects 
Using the network trained by PET images of AD and NC, PET images of MCI subjects 
were tested whether they would convert to AD or not. The labels of the output nodes of the 
CNN, AD and NC, were changed to MCI converter and nonconverter, as aforementioned 
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above. As the classification of AD/NC, we classified a patient as a predictive MCI converter 
if the probability of the network output layer was higher than 0.5. Sensitivity, specificity and 
accuracy were measured and ROC analysis was also performed using ConvScore.  
ConvScore was correlated with the longitudinal changes of cognitive measurements 
including CDR-SB, ADAS-Cog, FAQ and MMSE. Cognitive measurements of 1-year and 3-
year follow-up visits were compared with those of baseline studies to calculate longitudinal 
changes. Pearson correlation was used for the correlation analysis.   
 
Feature volume of interests based analysis 
To compare CNN-based biomarker with conventional quantification methods, feature 
volume of interests (VOIs)-based analyses for FDG and AV-45 PET were carried out. The 
images were processed and quantified by feature VOI as described previously 16-18. In brief, 
FDT PET volumes were spatially normalized with nonlinear warping process. Average FDG 
uptake from the angular (right/left), temporal (right/left) and posterior cingulate cortices were 
calculated. The quantification data were expressed relative to the mean uptake of a reference 
regions, pons and cerebellar vermis 16. For AV-45 PET, cortical uptake of AV-45 was 
calculated. Cortical regions were segmented with FreeSurfer, and used to extract mean AV-45 
uptake in frontal, anterior and posterior cingulate, lateral parietal, and lateral temporal 
regions. The overall cortical mean uptake value expressed relative to uptake in the whole 
cerebellum was used 17, 18. 
 
Statistics 
We compared the diagnostic and prediction accuracy of CNN with those of feature VOI-
based approach with McNemar’s nonparametric test. ROC analysis with area under the curve 
(AUC) measurement was performed for ConvScore and feature VOI-based parameters. The 
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AUCs were compared using a nonparametric test of DeLong for comparison of two 
correlated ROC curves 19. ConvScore was correlated with longitudinal changes of cognitive 
measurements using Pearson’s correlation. All statistical analysis was performed by using the 
MATLAB software. P-value < 0.05 was considered significant. 
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Results 
Results of AD classification and MCI conversion prediction 
We included a total of 492 subjects in this study. Among them, 139 patients were AD, 171 
patients were MCI and 182 were NC. Demographic data and cognitive measurements of each 
group were summarized in table 1.  
The classification accuracy of the CNN-based approach was compared with feature VOI-
based analysis of FDG and AV-45 PET as conventional quantitative analyses. Sensitivity, 
specificity and accuracy of CNN-based approach for classification between AD and NC were 
93.5%, 97.8% and 96.0%, respectively. They were significantly higher than those of VOI-
based analyses (p-values were summarized in table 2). Those for the prediction of MCI 
conversion was 81.0%, 87.0% and 84.2%, respectively. Specificity of CNN-based approach 
was significantly higher than VOI-based AV-45 PET. Sensitivity and accuracy were also 
higher compared with conventional methods, though it did not reach statistical significance 
(p-values were summarized in table 2).  
In addition to the group classification, we calculated quantitative score, ConvScore, for 
predicting MCI converters. It was obtained from the value of the last layer of the network. 
Using ConvScore, ROC curves were drawn and AUC were calculated (figure 2, table 2). 
AUC of ConvScore was significantly higher than feature-VOI based analysis for AD 
classification (p < 0.001 for deep CNN vs. FDG and vs. AV-45) and prediction of MCI 
conversion (p < 0.01 for deep CNN vs. FDG and p < 0.05 for deep CNN vs. AV-45).  
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Table 1. Demographic data 
 
Variables 
Normal  
(n=182) 
AD  
(n=139) 
p 
MCI converter  
(n=79) 
MCI nonconverter  
(n=92) 
p 
Age (years) 73.4±6.3 74.3±8.2 n.s. 72.3±7.2 70.3±6.3 n.s. 
Sex (M/F) 88/94 80/59 n.s. 43/36 51/41 n.s. 
Education (years) 16.6±2.5 15.8±2.7 <0.01 16.3±2.6 16.4±2.7 n.s. 
MMSE 29.0±1.2 23.0±2.1 <0.001 27.1±1.9 28.1±1.7 <0.001 
ADAS 9.1±4.5 31.0±8.6 <0.001 22.0±6.8 12.9±5.5 <0.001 
APOE ε4 (-/+) 130/52 (28.6%) 44/95 (68.3%) <0.001 22/57 (72.2%) 58/34 (37.0%) <0.001 
 
 
Table 2. Sensitivity, specificity and accuracy for the discrimination between AD and normal controls and the prediction for MCI converters.  
  Feature VOI-based   Deep learning-based 
approach  
p-value 
  FDG AV45   vs. FDG vs. AV45 
AD vs. Normal             
Sensitivity,% 84.2 81.8   93.5 0.004 <0.001 
Specificity,% 86.3 80.8   97.8 <0.001 <0.001 
Accuracy,% 85.4 80.7   96.0 <0.001 <0.001 
ROC AUC 0.91 0.84   0.98 <0.001 <0.001 
              
MCI Conversion Prediction             
Sensitivity,% 70.9 86.1   81.0 0.08 0.29 
Specificity,% 79.3 75.0   87.0 0.19 0.007 
Accuracy,% 75.4 80.1   84.2 0.02 0.21 
ROC AUC 0.82 0.83   0.89 0.006 0.03 
ROC: receiver operating characteristic; AUC: area under curve  
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Figure 2 ROC curves for deep CNN. ROC analyses were performed for the classification of AD (A) and the 
prediction of MCI conversion (B). ROC curves of feature VOI-based approaches using FDG and AV-45 PET 
were also drawn. Areas under curve (AUC) values were calculated. (A) AUC of ConvScore was significantly 
higher than feature-VOI based analysis for AD classification (AUC=0.98, 0.91 and 0.84 for ConvScore, FDG 
and AV-45, respectively; p < 0.001 for deep CNN vs. FDG and vs. AV-45) (B) AUC of ConvScore was also 
significantly higher than feature VOI-based analysis for prediction of MCI conversion (AUC=0.89, 0.82 and 
0.83 for ConvScore, FDG and AV-45, respectively; p < 0.01 for deep CNN vs. FDG and p < 0.05 for deep CNN 
vs. AV-45). 
 
 
Correlation of CNN-based biomarker with cognitive outcomes 
ConvScore calculated from baseline PET images of MCI patients was significantly 
correlated with the longitudinal change of cognitive measurements at 1 year and 3 years 
(figure 3). ConvScore was significantly positively correlated with longitudinal change of 
CDR-SB (r=0.37, p<0.0001 at 1 year and r=0.63, p<0.0001 at 3 years), ADAS-Cog (r=0.29, 
p=0.0001 at 1 year and r=0.24, p=0.004 at 3 year) and FAQ (r=0.40, p<0.0001 at 1 year and 
r=0.67, p<0.0001 at 3 year). It was significantly negatively correlated with MMSE (r=-0.30, 
p<0.0001 at 1 year and r=-0.61, p<0.0001 at 3 year). Note that the changes were steeper for 
the measurements at 3 years compared with 1 year. ConvScore of MCI converters was 
significantly higher than that of MCI nonconverters (2.40±1.49 and -0.13±1.36, respectively. 
p<0.0001) (figure 4). ConvScore could be used as a quantitative biomarker for predicting 
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longitudinal cognitive measurements decline in MCI patients as well as conversion to AD.  
 
 
 
 
Figure 3 Correlation between output of the network and longitudinal changes of cognitive measurements. 
The last layer provides an output scores for AD or MCI converter, which are defined as ConvScore. Cognitive 
measurements at baseline, 1 year, and 3 years were obtained for each MCI patient and ConvScore was 
correlated with the longitudinal change of them. (A-D) ConvScore was significantly correlated with the change 
of Cognitive Dementia Scaling Sum of Boxes (CDR-SB) (r=0.37, p<0.0001), Alzheimer Disease Assessment 
Scale-Cognitive Subtest (ADAS-Cog) (r=0.29, p=0.0001), Functional Activities Questionnaire (FAQ) (r=0.40, 
p<0.0001) and Mini-mental State Examination (MMSE) (r=-0.30, p<0.0001) from baseline to 1 year follow-up. 
(E-H) The significant correlation between ConvScore and the change of the measurements from baseline to 3 
years was also found (r=0.63, p<0.0001 for CDR-SB; r=0.24, p=0.004 for ADAS-Cog; r=0.67, p<0.0001 for 
FAQ; r=-0.61, p<0.0001 for MMSE). 
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Figure 4 ConvScore of MCI converters and nonconverters. MCI converters were significantly higher 
ConvScore than nonconverters (2.40±1.49 and -0.13±1.36, respectively. p<0.0001). 
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Discussion 
In the present study, we developed a deep learning-based diagnostic method for 
predicting cognitive decline in MCI patients. According to our knowledge, we firstly applied 
recent deep CNN to multimodal PET images to predict future outcome. Deep CNN could 
accurately classify patients’ diagnostic group with the minimal steps of image processing and 
provide a quantitative biomarker for predicting cognitive outcome. Accordingly, the 
prediction of cognitive decline in our method could be automatically made by simply 
inputting subjects’ images. Output value (ConvScore) was significantly correlated with the 
longitudinal change of cognitive measurements.  
Previous PET imaging biomarkers relied on the uptake value in a set of regions of interest 
developed a priori or whole-cortical uptake value 6, 9, 10. To obtain these values, several image 
processing steps such as spatial normalization and cortical segmentation using structural MRI 
were required. However, such processing was not standardized and nonlinear image 
transformation could introduce a potential source of errors particularly in morphological 
alterations 20, 21. Our proposed method used spatially unnormalized baseline image data of 
AD and NC. It suggests that our approach is simply able to be utilized to redesign the 
voxelwise brain imaging processing pipeline which has routinely implemented normalization 
to template space. Furthermore, accuracy of differentiation between MCI converter and 
nonconverter (84.2%) outperformed the conventional feature-VOI methods to discriminate 
MCI converters. ROC comparison results also revealed that the accuracy of prediction was 
significantly higher than other methods. It is the benefit of deep CNN that could 
automatically discover the optimal features for image classification 11. Furthermore, the 
accuracy also outperformed other state-of-the-art machine-learning algorithms based on 
feature selection from multiple images for this differentiation problem 22-25, though those 
studies used different imaging modalities and clinical variables.  
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Our approach could provide a quantitative variable, ConvScore, to be used as a fusion 
biomarker for multiple PET images. As an imaging biomarker, low glucose metabolism and 
high amyloid deposit in the cortex at baseline can predict the longitudinal decline of cognitive 
scores 16, 17. However, a combined parameter considering both metabolism and amyloid 
deposit has been needed. ConvScore is not only a fusion biomarker directly obtained by both 
PET images, but strongly correlated with longitudinal cognitive measurements. It suggests 
cognitive functions of patients with high ConvScore at baseline could be rapidly deteriorated. 
This strong correlation is an important observation that has impact on clinical trials for early 
treatment intervention in prodromal AD. ConvScore could help select the subjects who would 
benefit from treatment in the clinical trials.  
In the clinical setting, most imaging studies are assessed by experts’ visual analysis, 
because it is simpler and more practical than the quantitative assessment which needs time-
consuming procedures. Deep CNN is motivated by human visual perception, which 
hierarchically processes recognized images in the cerebral cortex 26. As hierarchical features 
of images are automatically trained by data, manual feature selection or image processing 
steps can be minimized in deep CNN 11, 26. Therefore, after the training, the network is 
automatically able to analyze patients’ images by simply inputting subjects’ images. 
Considering the ease of application, the CNN-based image interpretation system has a large 
potential to be used in development of biomarkers of several diseases including cancer, 
cardiovascular disorders as well as neurodegenerative diseases.  
Recent remedies of CNN for achieving higher accuracy are increasing the depth of the 
network 27. However, to learn a deeper neural network, more image data will be essential. As 
the network is trained by the larger data, the higher performance it shows. In our study, to 
overcome the limited number of imaging data, PET images were augmented by flipping 
image in left-right direction. It was based on the previous knowledge that AD and MCI 
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converters showed symmetrically decreased FDG uptake and increased AV-45 uptake in the 
cerebral cortices. The network trained without this augmentation process showed 89.4% and 
81.3% accuracy for the differentiation between AD and NC and predicting MCI converters, 
respectively. Though the augmentation process increased the performance of the network, it 
might cause potential error in the classification because the two brain hemispheres have 
partly different functions. In the future, larger image data cohort and deeper network 
architecture could improve the CNN-based approach.  
Our deep CNN-based approach could predict cognitive decline in MCI patients with very 
high accuracy. For testing whether a MCI subject would convert to AD, baseline PET images 
without spatial transformation were needed as a feature extraction was automatically 
performed in multiple layers of the network. As a future work, our approach may be 
additionally used in completely independent cohorts. In addition, as an accurate biomarker, it 
could help select appropriate prodromal patients who benefit from early intervention.  
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